Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 6/20 | 0.37 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21134977 | 0.90 | ACE (0.46) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21135091 | 0.90 | ACE (0.46) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21134850 | 0.90 | ACE (0.46) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21134859 | 0.90 | ACE (0.46) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21153021 | 0.90 | ACE (0.46) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21134716 | 0.90 | ACE (0.46) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21134801 | 0.90 | ACE (0.46) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21134714 | 0.87 | BMP1 (0.46) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL11112354 | 0.86 | ACE (0.42) | ACEKDM4EMAPTTHRBALOX15 | |
| Hydrochloric Acid SCHEMBL11111556 | 0.84 | ACE (0.41) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202779-A1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | SHANGHAI KECHOW PHARMA, INC. (CN) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202779-A1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | MGMT, PRMT8, SULT1A1 | ACE 4638/4885KDM4E 3896/4885MAPT 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.